Defeat Duchenne Canadian Conference 2021: Addressing Duchenne muscular dystrophy (DMD) Standards of Care in Canada
The Neuromuscular Disease Network for Canada (NMD4C) in partnership with Jesse’s Journey and Muscular Dystrophy Canada (MDC), is proud to announce the inaugural Defeat Duchenne Canadian Conference, the first national summit solely focused on Duchenne muscular dystrophy (DMD) for health care providers across Canada.
The theme for this year’s virtual event is DMD standards of care (SoC). This three-part conference will bring together subject matter experts from pediatric and adult care for a comprehensive overview of the Canadian adaptation to the international DMD care considerations published in 2018.
What: Defeat Duchenne Canadian Conference: Addressing DMD Standards of Care in Canada
Who should attend: Multidisciplinary health care professionals involved in the care of DMD patients.
Session 1 (of 3): The first session will focus on the following DMD topics:
• Endocrinology management and bone health
• Cardiac management
• Pulmonary management
Friday, June 18, and Saturday, June 19, 2021, from 11 a.m. – 2 p.m. EDT each day. The second and third sessions will take place in September and December – stay tuned for registration later in the year.
Where: Online (Whova + Zoom)
We hope you and your team will join Jesse’s Journey and our partners as we build the future for Duchenne muscular dystrophy in Canada through research and collaboration.
First session of the three-part virtual conference starts June 18 and 19, 2021. Learn more about the sessions and speakers, and register today: www.dmdcanadianconference.com
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.